A newly opened study for metastatic HER2-negative breast cancer will evaluate an alternative systemic treatment combination that omits or delays the use of chemotherapy while improving the efficacy and durability of response. The Providence-initiated study combines two potentially effective and previously studied strategies: an androgen receptor blockade (bicalutamide) and immune checkpoint therapies (nivolumab, a PD-1 inhibitor, and ipilimumab, a CTLA-4 inhibitor).
Medical oncologist David Page, M.D., the study’s designer and principal investigator, is part of the research team at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Dr. Page is a member of the National Cancer Institute’s Breast Cancer Immuno-Oncology Task Force, which advises investigators from around the world on the development of immunotherapy for breast cancer. He currently serves on the leadership teams of several international clinical trials evaluating immunotherapy and combination therapies for breast cancer.
For more information about this study, or to enroll a patient, call our Clinical Research office at 503-215-2614.
See more breast cancer studies
More than 20 research studies investigating a broad spectrum of breast cancer therapies and interventions are currently open at Providence Cancer Institute. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from our own investigator-initiated research studies to large international studies, including studies from the National Cancer Institute and from pharmaceutical industry partners.
New studies are added frequently. Please visit our website to see all breast cancer studies currently open at Providence Cancer Institute.
A team of breast cancer specialists
The research team at the Earle A. Chiles Research Institute at Providence Cancer Institute includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused research nurses, laboratory scientists, data coordinators and lab assistants. Every person on this team is passionate about providing the best possible care and the best available study options for patients with breast cancer.